Published Before-and-After Photos Highlight Dramatic Improvements in Netherton Syndrome Patient Treated with QRX003 New York, January 07, 2024 -PRISM MediaWire - PRISM MarketView has released an exclusive interview with Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) CEO Dr. Michael Myers, who shares the company’s notable interim data in its ongoing Netherton Syndrome clinical trials. Quoin, a clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, is addressing unmet...